Photochemistry and Photobiology · 1987 · 105 citations · 3 references
EngineeringOncologyBiomedical OpticsBiophotonicsOncologic ImagingBiomedical Laser ApplicationsMolecular Imaging In OncologyPhotodynamic TherapyAutofluorescenceAutofluorescence ImagingContrast EnhancementFluorescence Contrast AgentsTissue Autofluorescence
Abstract Visible detection of early stage cancer labelled with the fluorescing porphyrin mixture of dihematoporphyrin‐ether and dihematoporphyrin‐ester (DHE) is often limited by a high and inhomogeneously distributed level of autofluorescence. A new imaging method for reducing autofluo‐rescence is described. The method uses alternating fluorescence excitation with laser light in the violet and blue spectral ranges. Subtraction of the corresponding fluorescence images results in contrast enhancement due to an effective reduction in the autofluorescence contribution. A prototype version of a highly sensitive fluorescence imaging device including a modified krypton ion laser, an image‐intensified solid‐state TV‐camera, a digital image‐processing system, and video recording and monitoring has been developed. Experiments performed with this fluorescence imaging system on a tumorous dog bladder showed that a dose of 0.2 mg DHE kg −1 body wt, which is far below the dose administered for photodynamic therapy (2‐5 mg kg − ’body wt), is sufficient to give a high‐contrast fluorescence image. The corresponding excitation power density was about 1 W m −2 . Photobleaching of DHE was observed during fluorescence detection at excitation power densities exceeding 1 kW m −2 . At these high excitation levels DHE fades out nearly completely within 0.25 min.
3
Effect of bleaching of porphyrin sensitizers during photodynamic therapy
Johan Moan · Cancer Letters · 1986 · 125 citations